Martínek's life was saved by an experimental treatment abroad. Many Czechs don't get it through a complicated process.

Deník NIndependentCenterFactual 85Objective 604 days ago

The article discusses the growing role of medical cannabis in Czech medicine, highlighting both its potential benefits and the systemic challenges faced by patients. It begins with the personal story of a woman named Vera, who suffered from borreliosis (Lyme disease), and describes her difficult treatment journey involving antibiotics and subsequent side effects. The piece raises questions about which diagnoses could benefit from cannabis-based treatments and who truly experiences relief. However, the article ends abruptly due to subscription restrictions, leaving the full discussion incomplete.

Bias read (Center): While the article touches on healthcare policy and the legal status of medical cannabis, it does not take a clear ideological stance. The focus remains on patient experiences and systemic barriers rather than promoting a specific political agenda. The narrative is balanced between describing the困境 (

Why these scores (Factual 85 · Objective 60): Factuality is high as the article discusses real-world medical cases and challenges with cannabis-based treatments. However, it lacks specific data from the EU Clinical Trials Register and presents anecdotal evidence rather than verified clinical trial outcomes. Objectivity is lower due to emotional

Novinky.czIndependentCenterFactual 75Objective 706 days ago

The article discusses the challenges faced by Czech patients seeking experimental treatments through international clinical trials for rare diseases. Rare diseases affect fewer than five people per ten thousand and often have significant impacts on quality of life or even threaten survival. These conditions are frequently genetic, and diagnosis can take years due to their rarity. Patients often turn to international clinical trials as a last resort when standard treatments fail. The process involves contacting the State Institute for Drug Control (SÚKL), navigating foreign registries like the EU Clinical Trials Register, overcoming communication barriers, and coordinating care between local and foreign medical teams. The article highlights the complexity and cost involved, including travel expenses and lost income, which many patients cannot afford. It also mentions efforts by organizations like the Czech Association of Patients with Rare Diseases (ČAVO) and SÚKL to simplify access to these treatments.

Bias read (Center): While the issue of access to experimental treatments for rare diseases is politically sensitive, the article presents a balanced view of the challenges faced by patients and the efforts being made by both patient advocacy groups and regulatory bodies. There is no overt ideological slant in the tone,

Why these scores (Factual 75 · Objective 70): Factuality is moderate as it references the EU Clinical Trials Register and mentions challenges in accessing international trials. It provides some context about rare diseases and patient access issues. Objectivity is better as it presents both systemic barriers and patient experiences without overt